Enabling precision medicine in type 1 diabetes (T1D): leveraging integrative multiomics to understand T1D endotypes for therapy

实现 1 型糖尿病 (T1D) 的精准医疗：利用综合多组学了解 T1D 内型以进行治疗

• 批准号: 491380
• 负责人: Sung Hyekyoung
• 金额: $ 13.13万
• 依托单位: York University (Toronto, Ontario)
• 依托单位国家: 加拿大
• 项目类别: Fellowship Programs
• 财政年份: 2023
• 资助国家: 加拿大
• 起止时间: 2023-05-01 至 2026-05-01
• 项目状态: 未结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=491380&lang=en
• 关键词: Adiponectin; Beta Cell; Innate Immunity; Insulin; Microbiome; Regulatory T Cell (Treg); Type 1 Diabetes (T1d); Adiponectin; Beta Cell; Innate Immunity; Insulin; Microbiome; Regulatory T Cell (Treg); Type 1 Diabetes (T1d)

Type 1 diabetes (T1D) is a devastating autoimmune disease affecting over 300,000 Canadians. It is characterized by the destruction of the cells that produce insulin. These are located in the pancreas. One reason for this is unwanted activation of cells in

1型糖尿病（T1D）是一种毁灭性的自身免疫性疾病，影响了30万加拿大人。它的特征是破坏产生胰岛素的细胞。这些位于胰腺。原因之一是细胞中细胞的激活